Takeda Pharmaceutical Co. Ltd. is providing substantial launch support to a new US venture focusing on novel regenerative approaches to serious liver diseases, in a move the company says aligns with its strategic focus areas.
The Japanese firm has committed total funding of $100m to Ambys Medicines, including participation in the start-up’s $60m Series A...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
